Description

Multilevel lumbar spinal fusion and decompression surgeries (LSS) are common and extremely painful inpatient procedures associated with severe post-surgical pain, high incidence of CPSP, persistent and excessive opioid use, unsafe opioid prescribing and development of opioid use disorder (OUD), along with costly immediate postoperative opioid adverse events (AEs) and long hospital stays. Opioids are still widely used to manage acute surgical pain and remain a core component of multi-modal analgesic and enhanced recovery after surgery protocols (ERAS) for painful surgeries. About half of LSS patients suffer from uncontrolled severe surgical pain and significant adverse opioid effects due to opioids' narrow therapeutic indices and unpredictable inter-individual variations in pain perception and opioid responses. Risks associated with perioperative opioid use include immediate risks (life-threatening respiratory depression (RD), excessive sedation, postoperative nausea and vomiting (PONV), urinary retention, constipation, ileus and itching) that frequently delay recovery, require additional treatment or monitoring, increase cost of care, and prolong hospital stay. Long-term risks include opioid dependence, opioid-use disorder (OUD), and the consequent personal, financial and societal fall-out from opioid addiction.

While in the hospital, LSS patients report suboptimal surgical pain (and AEs) with short-acting opioids such as morphine, hydromorphone, and fentanyl. Post-discharge, despite receiving additional potent prescribed opioids such as oxycodone for >1-2 weeks at home, 20-50% of patients develop CPSP, largely due to suboptimal immediate surgical pain relief (the single greatest risk factor for CPSP). Patients who develop CPSP have high life-long risks for opioid use and misuse, contributing to the ongoing opioid epidemic and lost productive life. Poor surgical pain relief and opioid- AEs therefore result in negative consequences for patients, families, providers, and society, and constitute significant socio-economic burden. Thus, there is an urgent and unmet clinical need for a reliable and proactive tool to reduce opioid use and opioid-related AEs, enhance pain relief and prevent CPSP following painful surgeries.

CPSP is common following LSS: Effective and aggressive acute surgical pain management is critical to lower risks of developing CPSP. In a large prospective study assessing pain outcomes from 21 hospitals in 11 European countries (PAIN OUT cohort)120, 11.8% of patients reported moderate to severe CPSP at 12 months. The three risk factors for CPSP at 12 months, chronic preoperative pain, type of surgery and percentage of time in severe acute surgical pain, are very common in LSS patients. Importantly, orthopedic surgery is associated with 3-fold higher risk for CPSP compared with all other procedures. A 10% increase in the percentage of time in severe pain on the first postoperative day was associated with a 30% increase in the incidence of CPSP at 12 months (N=889). LSS is often associated with severe acute post-surgical pain, a high incidence of CPSP, excessive and persistent opioid use increasing cost of care significantly with high worker compensation costs with lost productivity. Thus, there is a clear need for more effective and safer pain management following LSS to prevent CPSP, risks of lost productivity, excessive opioid use, misuse, dependence and OUD.

High inter-individual variations in response to opioids can be explained by genetics and clinical risk factors, yet translational barriers prevent widespread adoption of genotype-guided care: Our many studies on genetic predictors of postoperative pain and opioid-related AEs, and published literature from other researchers demonstrate that genetic and clinical factors are associated with inter-individual variations in pain control and adverse outcomes with different opioids. Through genotype-based opioid selection, precision dosing and outpatient tailored opioid prescribing improve outcomes, there are many translational barriers. An important example is the use of CYP2D6 phenotyping to guide dosing or use of codeine, tramadol, hydrocodone, and oxycodone for improved safety and efficacy.

OpalGenix intends to revolutionize perioperative opioid and pain management with proactive and personalized risk prediction algorithms with >70% accuracy in predicting opioid AEs for precision pain and opioid management. GPS-Opioid will be a 510(k) cleared medical device that will enable preoperative genotyping of important and patented polygenetic markers shown to impact clinically and economically meaningful perioperative opioid and pain outcomes. The polygenetic markers predict opioid AEs better than single-gene associations: each gene, including CYP2D6, explains only 5-10% of clinical response variations while polygenetic models have >70% predictive accuracy as they combine important pharmacodynamics genes with well-known but less important genes involved in opioid metabolism such as CYP2D6. In addition, polygenetic models account for the synergistic effects of multiple risk alleles. Uniquely, GPS-Opioid also includes patented clinical risk factors with polygenetic signatures using a proprietary algorithm to identify patients at risk for experiencing uncontrolled severe pain, opioid-related AEs including RD and PONV, prolonged hospital stay, CPSP, opioid dependence and potential for developing OUD. Integration of GPS-Opioid in EHR, at the point-of-care, will enable perioperative clinicians with critical information they need to develop a personalized ERAS pain management plan prior to surgery to proactively minimize/eliminate costly opioid related adverse events, enhance surgical pain relief and avoid CPSP